Brinter Launches New Visco Bio Printing Heads with Puredyne Bioprinting

Brinter Launches New Visco Bio Printing Heads with Puredyne Bioprinting

Finnish bioprinting startup Brinter released the new extrusion-based Visco Bio medical print head for its Brinter bioprinters. The new modular print heads enable nearly zero dead volume, meaning that expensive medical grade material waste is cut to a minimal level. The Finnish company continues to develop and implement new features to its device on the back of a strong first year’s growth year in 2021.

Prellis Biologics to provide human lymph node organoids for research Bioprinting

Prellis Biologics to Provide Human Lymph Node Organoids for Research

Prellis Biologics Inc., a biotherapeutics company with human tissue engineering capabilities, has entered into a collaboration and license option agreement with Sanofi S.A., an innovative global healthcare company. The collaboration will focus on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS), and leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs) and recreate immune responses in vitro to deliver antibodies with significant genetic diversity.

Carl Zeiss Meditec and Precise Bio to develop fabricated corneal tissue Bioprinting

Carl Zeiss Meditec and Precise Bio to Develop Fabricated Corneal Tissue

Carl Zeiss Meditec, one of the world’s leading medical technology companies, and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.

Humabiologics partners with Fisher Scientific Bioprinting

Humabiologics Partners with Fisher Scientific Bioprinting

Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers, and Fisher Scientific, a global leader in life sciences, are partnering to serve researchers in academia and industry who are working on regenerative medicine research.

4ff6bc905e94e7a8a392ed347f714d8b.jpg

Fluicell Launches Biopixlar AER for Compact Single-cell Bioprinting

Swedish bioprinting company Fluicell launched its second single-cell 3D bioprinter: the new Biopixlar AER is a compact 3D bioprinter that lets users create detailed biological tissues with high precision. It is the world’s first microfluidic high-precision bioprinter that fits inside a standard flow hood or biosafety cabinet. Fluicell designed it for high automation and easy workflow integration, with the goal of bringing Biopixlar technology to new customer segments.

Nanoscribe and CELLINK Join Forces to Release Quantum X Bio 2PP Bioprinter

Nanoscribe and CELLINK Join Forces to Release Quantum X Bio 2PP Bioprinter

Nanoscribe and CELLINK, two BICO companies, today jointly unveiled the Quantum X bio, a revolutionary system as part of the Nanoscribe Quantum X platform providing researchers with a very accurate 3D bioprinter. The Quantum X bio is the first-of-its-kind bioprinter enabling submicron printing resolution. Powered by Two-Photon Polymerization (2PP), the Quantum X bio is the premier tool for miniaturizing bioprinting to redefine the development of complex tissue or cell scaffolds and of advanced biomedical applications.

Bioprinting Company REGEMAT3D to Open Equity crowd funding round 3D Printer Hardware

Bioprinting Company REGEMAT3D to Open Equity Crowd Funding Round

Bioprinter manufacturer REGEMAT3D is launching a new equity crowdfunding round, that will help the company further scale its business and product lines while preparing for an IPO set to take place in 2023. At 3dpbm we usually do not cover crowdfunding campaigns for new products, however, this initiative is relative to a company that is already present in the market and has been making significant progress in the bioprinting segment. REGEMAT3D promises massive returns (up to 3 to 4 times the investment) and while the actual success of this financial initiative is subject to the same risks as any financial venture, the overall bioprinting segment is in fact growing up rapidly.